Researcher
Pieter Van Der Veken
- Research Expertise:Medicinal chemistry & drug discovery, pharmaceutical chemistry, organic chemistry & organic synthesis
- Keywords:ORGANIC CHEMISTRY, MEDICINAL CHEMISTRY, DRUG DISCOVERY, Pharmacy and pharmacology
- Disciplines:(Bio)molecular modelling and design, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Bio-organic chemistry, Organic chemical synthesis, Medicinal chemistry
- Research techniques:Drug design, organic synthesis, characterization of molecules via NMR spectroscopy, mass spectrometry and other analytical techniques
- Users of research expertise:Pharmaceutical and biotech-industry
Affiliations
- Medicinal Chemistry (UAMC) (Research group)
Member
From1 Oct 2003 → Today
Projects
21 - 30 of 74
- The role of dipeptidyl peptidase 9 (DPP9) in human monocyte-derived macrophages: Discovery of DPP9 binding partners & natural substrates using novel chemical and cellular tools.From1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- Validation of autophagy induction as a therapeutic strategy: from drug discovery and preclinical evaluation to safety investigation and biomarker research.From1 Jan 2021 → TodayFunding: BOF - projects
- Autophagy in inflammation and inflammatory disorders (ATLANTIS), from basicinsights to experimental therapy.From1 Jan 2021 → TodayFunding: BOF - iBOF
- Treatment of autophagy deficits in Charcot-Marie-Tooth disease caused by mutations in the small heat shock proteins HSPB1 and HSPB8.From1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
- Exploring a novel class of autophagy-inducing small molecules: chemical/biological investigation, target identification and validation in a mouse model of atherosclerosis.From1 Nov 2020 → 31 Oct 2023Funding: FWO senior postdoctoral fellowship
- Biopharmaceutical optimization of PET-diagnostic tools targeting fibroblast activation protein (FAP).From1 May 2020 → 30 Sep 2021Funding: IOF - technology validation in lab
- Cell death detection platform.From1 Jan 2020 → 31 Dec 2021Funding: BOF - scientific equipment program
- Design and synthesis of activity-based biomarker probes for fibroblast activation protein alpha (FAP-alpha).From1 Dec 2019 → 30 Nov 2020Funding: BOF - projects
- Pharmacological modulation of autophagy in vascular disease.From1 Dec 2019 → 30 Nov 2023Funding: BOF - projects
- Development of tools and methods for the evaluation of FAP as a predictive/prognostic biomarker in cancer.From1 Nov 2019 → 31 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 129
- UPLC-TQD-MS/MS method validation for quality control of alkaloid content in lepidium meyenii (Maca)-containing food and dietary supplements(2024)
Authors: Ngoc Thao Hien Le, Kenn Foubert, Mart Theunis, Tania Naessens, Murat Bozdag, Pieter Van Der Veken, Luc Pieters, Emmy Tuenter
Pages: 1 - 11 - Design and synthesis of selective DPP9 inhibitors(2024)
Authors: Siham Benramdane, Pieter Van Der Veken, Hans De Winter
Number of pages: 232 - Next generation fibroblast activation protein (FAP) targeting PET tracers(2023)
Authors: Christian B.M. Poulie, Vladimir Shalgunov, Filipe Elvas, Yentl Van Rymenant, Euy-Sung Moon, Umberto Maria Battisti, Joni De Loose, Ingrid De Meester, Frank Rösch, Pieter Van Der Veken, et al.
Pages: 1 - 10 - From PERK to RIPK1(2023)
Authors: Camilla Scarpellini, Sophie Valembois, Kenneth Goossens, Mike Vadi, Caroline Lanthier, Greta Klejborowska, Pieter Van Der Veken, Hans De Winter, Mathieu J.M. Bertrand, Koen Augustyns
Pages: 1 - 15 - Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics(2023)
Authors: Marcel Martin, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Joni De Loose, Emile Verhulst, Ingrid De Meester, Pieter Van Der Veken, Frank Roesch
Pages: 1 - 25 - Characterization of structurally diverse ¹⁸F-labeled d-TCO derivatives as a PET probe for bioorthogonal pretargeted imaging(2023)
Authors: Karuna Adhikari, Christel Vangestel, Pieter Van Der Veken, Sigrid Stroobants, Filipe Elvas, Koen Augustyns
Pages: 38252 - 38262 - Chemically diverse activity-based probes with unexpected inhibitory mechanisms targeting trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Lisse Decraecker, Valerie Cacheux, Irena Zeiburlina, Michelle De bruyn, Louise Battut, Carlos Moreno Cinos, Davide Ceradini, Eric Espinosa, Gilles Dietrich, et al.
Pages: 1 - 17 - Design, synthesis and evaluation of novel activity-based probes and inhibitors for trypsin-like serine proteases(2023)
Authors: Alba Ramos Llorca, Koen Augustyns, Pieter Van Der Veken
Number of pages: 289 - Highly selective inhibitors of dipeptidyl peptidase 9 (DPP9) derived from the clinically used DPP4-inhibitor vildagliptin(2023)
Authors: Siham Benramdane, Joni De Loose, Nicolò Filippi, Margarida Florindo Espadinha, Olivier Beyens, Yentl Van Rymenant, Laura Dirkx, Murat Bozdag, Koen Augustyns, Guy Caljon, et al.
Pages: 12717 - 12738 - Vildagliptin‐derived dipeptidyl peptidase 9 (DPP9) inhibitors(2022)
Authors: Siham Benramdane, Joni De Loose, Olivier Beyens, Yentl Van Rymenant, Gwendolyn Vliegen, Koen Augustyns, Hans De Winter, Ingrid De Meester, Pieter Van Der Veken
Pages: 1 - 16
Patents
1 - 10 of 10
- 3-(Benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.g. Stroke (Inventor)
- Bis(acetamidophenyl) guanidinophenyethylphosphonates for use in the prevention and/or treatment of PAR-related diseases. (Inventor)
- Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of par-related diseases (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- Halogenated benzotropolones as ATG4B inhibitors (Inventor)
- Halogenated benzotropolones as atg4b inhibitors (Inventor)
- 3-(benzylamino)-4-(cyclohexylamino)-n-(2-(piperazin-1-yl)ethyl)benzenesulfonamide derivatives and related ferrostatin-1 analogues as cell death inhibitors for treating e.G. stroke (Inventor)
- 3,4-diaminobenzenesulfonamide derivatives for inhibiting cell death (Inventor)
- KLK4 inhibitors (Inventor)